Novel next-generation sequencing and networks-based therapeutic targets: Realistic and more effective drug design and discovery

Current Pharmaceutical Design

Volumn 20, Issue 1, 2014, Pages 11-22

  Roukos, Dimitrios H ^a,b   Baltogiannis, Giannis G ^b   Katsouras, Christos S ^b   Bechlioulis, Aris ^b   Naka, Katerina K ^b   Batsis, Charalambos ^b   Liakakos, Theodore ^c   Michalis, Lampros K ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cancer; Cardiovascular disease; Drugs; Genetics; Genomics; Networks; Sequencing

Indexed keywords

ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; LONG UNTRANSLATED RNA; TRANSCRIPTION FACTOR; UNTRANSLATED RNA;

ARTICLE; BINDING SITE; CANCER THERAPY; CELL FUNCTION; CHEMICAL REACTION; CHROMATIN; CHROMOSOME; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL MEDICINE; DRUG APPROVAL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG TARGETING; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; INTRACELLULAR SIGNALING; NEOPLASM; NETWORKS BASED THERAPEUTIC TARGET; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REACTION ANALYSIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; GENE REGULATORY NETWORK; HIGH THROUGHPUT SEQUENCING; METABOLISM; METHODOLOGY; PROTEIN BINDING; REVIEW;

DRUG DESIGN; DRUG DISCOVERY; GENE REGULATORY NETWORKS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 84897137550     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282001140113122438     Document Type: Article

References (115)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11-30.
2. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Acute myocardial infarction in patients presenting with ST segment elevation (management of). (ESC). Eur Heart J 2012; 33: 2569-619.
3. Rask-Andersen M, Almén MS, Schiöth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011; 10(8): 579-90.
4. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet 2011; 12(1): 56-68.
5. Ideker T, Galitski T, Hood L. A new approach to decoding life: Systems biology. Annu Rev Genomics Hum Genet 2001; 2: 343-72.
6. Perc M, Gómez-Gardeñes J, Szolnoki A, Floría LM, Moreno Y. Evolutionary dynamics of group interactions on structured populations: A review. J R Soc Interface 2013; 10(80): 20120997.
7. Li MJ, Wang P, Liu X, et al. GWASdb: A database for human genetic variants identified by genome-wide association studies. Nucleic Acids Res 2012; 40(Database issue): D1047-54. doi: 10.1093/nar/gkr1182.
8. Roukos D. Integrative deep-sequencing analysis of cancer samples: Discoveries and clinical challenges. Pharmacogenomics J 2013; doi: 10.1038/tpj.2012.51.
9. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487(7407): 330-7.
10. Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: Genetic interactions create phantom heritability. Proc Natl Acad Sci USA 2012; 109: 1193-8.
11. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, et al. An integrated map ofgenetic variation from 1,092 human genomes. Nature 2012; 491(7422): 56-65.
12. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012; 337(6099): 1190-5.
13. ENCODE Project Consortium, Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489(7414): 57-74.
14. Stamatoyannopoulos JA. What does our genome encode? Genome Res 2012; 22(9): 1602-11.
15. Neph S, Stergachis AB, Reynolds A, Sandstrom R, Borenstein E, Stamatoyannopoulos JA. Circuitry and dynamics of human transcription factor regulatory networks. Cell 2012; 150(6): 1274-86.
16. Gerstein MB, Kundaje A, Hariharan M, et al. Architecture of the human regulatory network derived from ENCODE data. Nature 2012; 489(7414): 91-100.
17. Neph S, Vierstra J, Stergachis AB, et al. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature 2012; 489(7414): 83-90.
18. Thurman RE, Rynes E, Humbert R, et al. The accessible chromatin landscape of the human genome. Nature 2012; 489(7414): 75-82.
19. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature 2012; 489(7414): 109-13.
20. Ku CS, Roukos DH. From next-generation sequencing to nanopore sequencing technology: Paving the way to personalized genomic medicine. Expert Rev Med Devices 2013; 10(1): 1-6.
21. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486(7403): 400-4.
22. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486(7403): 395-9.
23. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486(7403): 405-9.
24. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486(7403): 353-60.
25. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486(7403): 346-52.
26. Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488(7413): 660-4.
27. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491(7424): 399-405.
28. Targeted Cancer Therapies. Available from: NIH. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
29. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 2012; 795: 1-34.
30. Roukos DH. Trastuzumab and beyond: Sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 2011; 11(2): 81-92.
31. Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011; 16(6): 800-10.
32. Verma S, Miles D, Gianni L, et al. for the EMILIA Study Group. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367(19): 1783-91.
33. Cho WC, Roukos DH. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: Genome landscape-based targets. Expert Rev Anticancer Ther 2013; 13(1): 5-8.
34. Gotlib J. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87(9): 903-14.
35. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-16.
36. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29(15): 2011-9. Available from: Http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm310933.htm
37. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin. Oncol 2009; 27(5): 663-671.
38. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377(9783): 2103-14.
39. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 2012; 30(15): 1755-62.
40. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 2012; 307(13): 1383-93.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
42. Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol 2012; 8: 565.
43. Pawson T, Linding R. Network medicine. FEBS Lett 2008; 582(8): 1266-70.
44. Roukos DH. Networks medicine: From reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 2011; 12(5): 695-8.
45. Vernot B, Stergachis AB, Maurano MT, et al. Personal and population genomics of human regulatory variation. Genome Res 2012 Sep; 22(9): 1689-97.
46. Schaub MA, Boyle AP, Kundaje A, Batzoglou S, Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res 2012; 22(9): 1748-59.
47. modENCODE Consortium; Roy S, Ernst J, Kharchenko PV et al. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science 2010; 330(6012): 1787-97 .
48. Goh KI, Choi IG. Exploring the human diseasome: The human disease network. Brief Funct Genomics 2012; 11(6): 533-42
49. Alberts B. Model organisms and human health. Science 2010; 330(6012): 1724.
50. Roukos DH. Differential signaling transduction networks for clinical robustness. Expert Rev Proteomics 2012; 9(2): 111-4.
51. Komurov K. Modeling community-wide molecular networks of multicellular systems. Bioinformatics 2012; 28(5): 694-700.
52. Chandra N, Padiadpu J. Network approaches to drug discovery. Expert Opin Drug Discov 2013; 8(1): 7-20. doi: 10.1517/17460441.2013.741119.
53. Shoemaker BA, Panchenko AR. Deciphering protein-protein interactions. Part I. Experimental techniques and databases. PLoS Comput Biol 2007; 3(3): E42.
54. Parrish JR, Gulyas KD, Finley RL Jr. Yeast two-hybrid contributions to interactome mapping. Curr Opin Biotechnol 2006; 17(4): 387-93.
55. Vasilescu J, Figeys D. Mapping protein-protein interactions by mass spectrometry. Curr Opin Biotechnol 2006; 17(4): 394-9.
56. Uetz P, Giot L, Cagney G, et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 2000; 403(6770): 623-7.
57. Tarassov K, Messier V, Landry CR, et al. An in vivo map of the yeast protein interactome. Science 2008; 320(5882): 1465-70.
58. Giot L, Bader JS, Brouwer C, et al. A protein interaction map of Drosophila melanogaster. Science 2003; 302(5651): 1727-36.
59. Li S, Armstrong CM, Bertin N, et al. A map of the interactome network of the metazoan C. elegans. Science 2004; 303(5657): 540-3.
60. Butland G, Peregrín-Alvarez JM, Li J, et al. Interaction network containing conserved and essential protein complexes in Escherichia coli. Nature 2005; 433(7025): 531-7.
61. [61]. Proteome organization in a genome-reduced bacterium. Science 2009; Kuhner, S., van Noort, V., Betts, M.J., et al 326, 1235-40.
62. Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005; 437(7062): 1173-8.
63. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: A resource for annotating the proteome. Cell 2005; 122(6): 957-68.
64. Ewing RM, Chu P, Elisma F, et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 2007; 3: 89.
65. Mewes HW, Albermann K, Heumann K, Liebl S, Pfeiffer F. MIPS: A database for protein sequences, homology data and yeast genome information. Nucleic Acids Res 1997; 25(1): 28-30.
66. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D. The Database of Interacting Proteins: 2004 update. Nucleic Acids Res 2004; 32(Database issue): D449-51.
67. Kerrien S, Alam-Faruque Y, Aranda B, et al. IntAct-open source resource for molecular interaction data. Nucleic Acids Res 35, D561-D565.
68. Chatraryamontri A, Ceol A, Palazzi LM, et al. MINT: The molecular interaction database. Nucleic Acids Res 2007; 35(Database issue): D561-5.
69. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human Protein Reference Database-2009 update. Nucleic Acids Res 2009; 37(Database issue): D767-72.
70. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: A general repository for interaction datasets. Nucleic Acids Res 2006; 34(Database issue): D535-9.
71. Zhang QC, Petrey D, Garzón JI, Deng L, Honig B. PrePPI: A structure-informed database of protein-protein interactions. Nucleic Acids Res 2013; 41(D1): D828-33.
72. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature 2012; 489: 101-8.
73. Tilgner H, Knowles DG, Johnson R, et al. Deep sequencing of subcellular RNA fractions shows splicing to be predominantly cotranscriptional in the human genome but inefficient for lncRNAs. Genome Res 2012; 22(9): 1616-25.
74. Mercer TR, Gerhardt DJ, Dinger ME, et al. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol 2011; 30: 99-104.
75. Derrien T, Johnson R, Bussotti G, et al 2012. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res (this issue). doi: 10.1101/gr.132159.111.
76. Harrow J, Frankish A, Gonzalez JM, et al 2012. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 2012; 22(9): 1760-74.
77. Howald C, Tanzer A, Chrast J, et al. Combining RT-PCR-seq and RNA-seq to catalog all genic elements encoded in the human genome. Genome Res 2012; 22(9): 1698-710.
78. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: A systematic review. J Natl Cancer Inst 2012; 104(7): 528-40.
79. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013 Feb 20.
80. Mattick JS 2009. The genetic signatures of noncoding RNAs. PLoS Genet 5: E1000459.
81. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 2008; 9: 102-114.
82. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252-63.
83. Carninci P, Kasukawa T, Katayama S, et al. The transcriptional landscape of the mammalian genome. Science 2005; 309: 1559-63.
84. Mercer TR, Dinger ME, Sunkin SM, Mehler MF, Mattick JS. Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci USA 2008; 105(2): 716-21.
85. Guttman M, Rinn JL. Modular regulatory principles of large noncoding RNAs. Nature 2012; 482(7385): 339-46.
86. Huarte M, Rinn JL. Large non-coding RNAs: Missing links in cancer? Hum Mol Genet 2010; 19(R2): R152-61.
87. Yang JH, Li JH, Jiang S, Zhou H, Qu LH. ChIPBase: A database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res 2013; 41(Database issue): D177-87.
88. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science 2002; 295: 1306-11.
89. Dostie J, Richmond TA, Arnaout RA, et al. Chromosome conformation capture carbon copy (5C): A massively parallel solution for mapping interactions between genomic elements. Genome Res 2006; 16(10): 1299-309.
90. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med 2011; 3(111): 111ra121.
91. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, et al. Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 2013; 12(2): 225-45. doi: 10.4161/cc.23274.
92. Scheer M, Grote A, Chang A, et al. BRENDA, the enzyme information system in 2011. Nucleic Acids Res 2011; 39(Database issue): D670-6.
93. Croft D, O’Kelly G, Wu G, et al. Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Res 2010; 39(Database issue): D691-7.
94. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2009; 38(Database issue): D355-60.
95. Kuhn M, von Mering C, Campillos M, et al. STITCH: Interaction networks of chemicals and proteins. Nucleic Acids Res 2008; 36(Database issue): D684-8.
96. Kuhn M, Szklarczyk D, Franceschini A, et al. STITCH 3: Zooming in on protein-chemical interactions. Nucleic Acids Res 2012; 40(Database issue): D876-80.
97. Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: A Free Tool to Discover Chemistry for Biology. J Chem Inf Model 2012; 52(7): 1757-68.
98. Chowdhary R, Tan SL, Zhang J, et al. Context-specific protein network miner-an online system for exploring context-specific protein interaction networks from the literature. PLoS One 2012; 7(4): E34480.
99. [100] von Eichborn J, Murgueitio MS, Dunkel M, et al. PROMISCUOUS: A database for network-based drug-repositioning. Nucleic Acids Res 2010; 39(Database issue): D1060-6.
100. [101] Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 2011; 27(3): 431-2.
101. [102] von Eichborn J, Bourne PE, Preissner R. Cobweb: A Java applet for network exploration and visualisation. Bioinformatics 2011; 27(12): 1725-6.
102. [103] Brown KR, Otasek D, Ali M, et al. NAViGaTOR: Network analysis, visualization and graphing toronto. Bioinformatics 2009; 25(24): 3327-9
103. [104] Garcia-Garcia J, Guney E, Aragues R, et al. Biana: A software framework for compiling biological interactions and analyzing networks. BMC Bioinformatics 2010; 11: 56.
104. [105] Lee SA, Chan CH, Chen TC, et al. POINeT: Protein interactome with sub-network analysis and hub prioritization. BMC Bioinformatics 2009; 10: 114.
105. [106] Assenov Y, Ramirez F, Schelhorn SE, et al. Computing topological parameters of biological networks. Bioinformatics 2008; 24(2): 282-4.
106. [108] Shmulevich I, Dougherty ER, Kim S, et al. Probabilistic Boolean Networks: A rule-based uncertainty model for gene regulatory networks. Bioinformatics 2002; 18(2): 261-74.
107. [109] Hickman GJ, Hodgman TC. Inference of gene regulatory networks using boolean-network inference methods. J Bioinform Comput Biol 2009; 7(6): 1013-29.
108. [110] Milo R, Shen-Orr S, Itzkovitz S, et al. Network motifs: Simple building blocks of complex networks. Science 2002; 298(5594): 824-7.
109. [111] Tyson JJ, Chen KC, Novak B. Sniffers, buzzers, toggles and blinkers: Dynamics of regulatory and signaling pathways in the cell. Curr Opin Cell Biol 2003; 15(2): 221-31.
110. [112] Mangan S, Alon U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci USA 2003; 100(21): 11980-5.
111. [113] Kholodenko BN. Cell-signalling dynamics in time and space. Nat RevMol Cell Biol 2006; 7: 165-76.
112. [114] Brandman O, Meyer T. Feedback loops shape cellular signals in space and time. Science 2008; 322(5900): 390-5.
113. [115] Wittmann DM, Krumsiek J, Saez-Rodriguez J, et al. Transforming Boolean models to continuous models: Methodology and application to T-cell receptor signaling. BMCSyst Biol 2009; 3: 98.
114. [116] Cheng TM, Gulati S, Agius R, Bates PA. Understanding cancer mechanisms through network dynamics. Brief Funct Genomics 2012; 11(6): 543-60.
115. [117] Davidich M, Bornholdt S. The transition from differential equations to Boolean networks: A case study in simplifying a regulatory network model. J Theor Biol 2008; 255(3): 269-77.